Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching

Le résumé fourni par la source

Abstract Purpose: To compare the outcomes of trimodal therapy (TMT) and radical cystectomy (RC) in the treatment of muscle-invasive bladder cancer (MIBC). Methods: Patients treated with either TMT or RC for MIBC at our institution between January 1998 and December 2022 were included. Propensity score matching was used to compare cancer-specific survival and overall survival rates. Results: A total of 93 patients who underwent TMT and 84 who underwent RC for MIBC were analyzed. In the TMT cohort, the pathological complete response rate was 65%; the 5-year recurrence-free survival rate, including intravesical recurrence, was 41.1%; and the 5-year bladder intact event-free survival rate was 55.8%. Using propensity score matching, 66 patients from each treatment group were selected for a comparative analysis of oncological outcomes. The 5-year distant metastasis-free, cancer-specific, and overall survival rates were 64.3% and 51.8% (P=0.096), 83.3% and 69.2% (P=0.104), and 77.8% and 64.2% (P=0.274) for TMT and RC, respectively. Subgroup analyses revealed that TMT for primary tumors significantly improved cancer-specific survival rates compared with RC. The two treatment types had similar adverse events related to hematologic toxicity during perioperative chemotherapy. Conclusion: TMT exhibited oncological outcomes comparable to those of RC in the treatment of MIBC, indicating that TMT provides favorable outcomes, particularly in cases of primary MIBC.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.